Immunotherapy involving PD-1/PD-L1 blockade has had some success with melanoma but is limited by lack of sufficient tumor infilation of activated lymphocytes to kill the cancer cells within the tumor in the majority of patients tested [5]. This evidence concerns the gene CD274 and neoplasm.